Is CBZ a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for CBIZ (CBZ) rests on Marcum integration and scale synergies: The 2024 Marcum acquisition roughly doubled CBIZ's size and created the largest middle-market accounting and advisory platform in the US. Revenue (TTM) is ~$2.8B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: CBIZ carries acquisition-related debt from the Marcum deal, so higher-for-longer interest rates and slower deleveraging are a risk to earnings. Whether CBZ is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
CBIZ, Inc. is a national professional-services firm that provides accounting and tax, financial advisory and consulting, employee benefits consulting, property and casualty insurance brokerage, and technology and managed IT services, primarily to middle-market businesses. It reports through three segments: Financial Services (the largest, covering accounting, tax, and advisory), Benefits and Insurance Services, and National Practices. Much of its revenue is recurring and fee-based, tied to compliance calendars, benefits renewals, and long-standing client relationships rather than a single product cycle. Its November 2024 acquisition of Marcum LLP, valued at roughly $2.3 billion, was the largest deal in its history and roughly doubled the company's scale, pushing combined annualized revenue toward $2.8 billion and making CBIZ the largest advisor of its kind in the US. The investment picture centers on integration and margin execution. Full-year 2025 revenue rose about 52% on the Marcum deal, and adjusted earnings grew sharply, but 2026 organic growth is guided to a more modest 2% to 5% as the one-time acquisition boost laps. Management has framed 2026 around finishing the Marcum integration, applying technology and AI to service delivery, and returning cash through buybacks. Underlying operating margins have softened as integration, technology, and facility costs work through the model, and reported quarterly profit has at times been flattered by acquisition-related accounting gains, so investors tend to focus on adjusted EBITDA and free cash flow to judge the true run-rate.
What's the case for buying CBZ?
1. Marcum integration and scale synergies
The 2024 Marcum acquisition roughly doubled CBIZ's size and created the largest middle-market accounting and advisory platform in the US. Management has said integration is largely complete with synergies tracking ahead of plan, which supports adjusted EBITDA of roughly $465 million to $475 million guided for 2026. Realizing cost savings and cross-selling across the enlarged client base is the central lever on profitability.
2. Recurring, fee-based revenue base
A large share of CBIZ revenue comes from recurring accounting, tax, benefits, and insurance work tied to regulatory and renewal calendars rather than discretionary spending. This gives the top line more stability than project-driven consultancies. The business does carry seasonality, with the first half weighted toward tax-season activity.
3. Technology, AI, and margin discipline
Management has positioned 2026 around applying technology and AI to service delivery while holding down non-labor costs. Widening adjusted margins after a period of integration spending is a key part of the story. Success would let modest revenue growth translate into faster earnings and free-cash-flow growth.
4. Capital returns and cash generation
CBIZ guides to free cash flow in the range of roughly $270 million to $290 million and has boosted share buybacks alongside its raised 2026 adjusted EPS outlook of about $4.00 to $4.10. Debt taken on for Marcum makes deleveraging and steady cash conversion important. Buybacks provide a per-share tailwind if organic growth stays in the low-to-mid single digits.
What are the risks to CBZ?
CBIZ carries acquisition-related debt from the Marcum deal, so higher-for-longer interest rates and slower deleveraging are a risk to earnings. Organic growth guided at only 2% to 5% leaves little margin for error, and integration, technology, and facility costs have pressured underlying operating margins even as reported profit was helped by one-time acquisition gains that will not recur. The business depends heavily on attracting and retaining accounting, tax, and advisory professionals in a tight labor market, and on middle-market client health that softens in a recession. Regulatory change in tax and benefits, competition from far larger accounting and insurance-brokerage firms, and integration missteps across a much larger combined workforce are additional risks, and the stock has re-rated lower despite raised guidance.
How is CBZ valued? (as of JULY 2026)
Snapshot for CBZ as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$2.8B
- Q1 2026 revenue: ~$848.6M (+1.3% YoY)
- 2026 revenue guidance: ~$2.8B to $2.9B (2-5% growth)
- 2026 adjusted EPS guidance: ~$4.00 to $4.10 (raised)
- 2026 adjusted EBITDA guidance: ~$465M to $475M
- Market cap: ~$2.1B
CBIZ traded around $40 in July 2026, with a trailing P/E near 15 and a forward P/E closer to 9 on guided adjusted earnings, well below its multi-year average multiple. The valuation compression reflects the shift from acquisition-fueled 52% revenue growth in 2025 to guided low-to-mid single-digit organic growth in 2026. Reported quarterly results have at times included large non-operating gains from Marcum acquisition accounting, so adjusted EBITDA and free cash flow are the cleaner gauges of the underlying run-rate.
How do you decide if CBZ is a buy?
Rather than asking whether CBZ is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CBZ indirectly through an index or sector ETF before adding more.
For the full picture, see the CBZ stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CBZ against your real portfolio and see your actual exposure before deciding.
The bottom line on CBZ
The bottom line: CBIZ's story right now is Marcum integration and scale synergies, with revenue (ttm) at ~$2.8B. If you believe that narrative continues, the call is about sizing CBZ sensibly and checking overlap with what you own; if you doubt it (the risk: cBIZ carries acquisition-related debt from the Marcum deal, so higher-for-longer interest rates and slower deleveraging are a risk to earnings.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around CBZ with Walnut
Use CBIZ as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is CBZ a good stock to buy right now?
+
The case for CBIZ right now is Marcum integration and scale synergies, with revenue (ttm) at ~$2.8B. If you believe that thesis holds, CBZ is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is cBIZ carries acquisition-related debt from the Marcum deal, so higher-for-longer interest rates and slower deleveraging are a risk to earnings. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does CBIZ do?
+
CBIZ, Inc.
What are the main risks of CBZ?
+
CBIZ carries acquisition-related debt from the Marcum deal, so higher-for-longer interest rates and slower deleveraging are a risk to earnings. Organic growth guided at only 2% to 5% leaves little margin for error, and integration, technology, and facility costs have pressured underlying operating margins even as reported profit was helped by one-time acquisition gains that will not recur. The business depends heavily on attracting and retaining accounting, tax, and advisory professionals in a tight labor market, and on middle-market client health that softens in a recession. Regulatory change in tax and benefits, competition from far larger accounting and insurance-brokerage firms, and integration missteps across a much larger combined workforce are additional risks, and the stock has re-rated lower despite raised guidance.
What does CBIZ do?
+
CBIZ, Inc. is a national professional-services firm serving mainly middle-market businesses. It provides accounting and tax, financial advisory and consulting, employee benefits consulting, property and casualty insurance brokerage, and technology and managed IT services, organized into Financial Services, Benefits and Insurance Services, and National Practices segments.
What is the ticker CBZ?
+
CBZ is the NYSE ticker for CBIZ, Inc. The company is a US-listed professional-services advisor, not to be confused with the private accounting partnerships it competes against. It is one of the few publicly traded pure-play middle-market accounting and advisory firms.
Why did CBIZ acquire Marcum?
+
CBIZ closed its acquisition of Marcum LLP in November 2024 in a cash-and-stock deal valued at roughly $2.3 billion, its largest ever. The combination roughly doubled CBIZ's scale, lifted combined annualized revenue toward $2.8 billion, and made it the largest advisor of its kind in the US middle market.
Is CBIZ profitable?
+
Yes. CBIZ has been consistently profitable, and full-year 2025 revenue rose about 52% with adjusted earnings up sharply on the Marcum deal. For 2026 the company raised adjusted EPS guidance to roughly $4.00 to $4.10, though some reported quarterly profit has been boosted by one-time acquisition-related gains.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell CBZ; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.